Syeda Naqvi
Pulmonary Disease · Morgantown, WVNPI 1932625480
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 60 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by GSK at 36.8% of the total. 2025 is the largest year on record at $814, more than ten times the $27 reported in 2022. That places this record below the midpoint for pulmonary disease clinicians in WV, where the typical reported total is $1,097.
Across 60 payments — averaging $21.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$467
- Regeneron Healthcare Solutions, Inc.$392
- AstraZeneca$103
- Merck$74
- Inspire Medical Systems, Inc.$50
- United Therapeutics Corporation$41
- plus $144 from 5 others
What the payments were for
- Food & beverage$1,271100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 25 | $467 |
| Regeneron Healthcare Solutions, Inc. | 16 | $392 |
| AstraZeneca | 5 | $103 |
| Merck | 3 | $74 |
| Inspire Medical Systems, Inc. | 2 | $50 |
| United Therapeutics Corporation | 2 | $41 |
| Amgen | 2 | $34 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $34 |
| Ambu Inc. | 1 | $27 |
| Verona Pharma, Inc. | 1 | $25 |
| Actelion Pharmaceuticals US, Inc. | 1 | $24 |
How this compares
$1,271 in reported general payments places this provider in the 50th percentile of 89 pulmonary disease providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 61 | $41,078 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $11,862 |
| Advair HfaFluticasone Propion/Salmeterol | 15 | $7,244 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 50 | $7,145 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 16 | $7,093 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 39 | $1,051 |
| Ventolin HfaAlbuterol Sulfate | 11 | $774 |
| Montelukast Sodium | 23 | $295 |
| Prednisone | 28 | $92 |
| Doxycycline Hyclate | 11 | $36 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta | $467 | $48,17177 claims |
| AstraZenecaBreztri Aerosphere | $103 | $11,86214 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 89 pulmonary disease providers in West Virginia.
Other pulmonary disease in Morgantown
- Roger AbrahamsMorgantown$133K
- Peter KochupuraMorgantown$22K
- Sidharth BhasinMorgantown$7K
- Andrzej JaworskiMorgantown$5K
- Kyle ChapmanMorgantown$5K
- Haroon AhmedMorgantown$4K
- Mehdi FarishtaMorgantown$4K
- Sarah HadiqueMorgantown$4K
- Srinivasa PotlaMorgantown$3K
- Robert StansburyMorgantown$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.